Expert perspectives on cholangiocarcinoma (CCA)

CCA: under the spotlight (2021)

This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty who critically discussed the complexity of diagnosing CCA and the clinical and genetic heterogeneity associated with the disease

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Dr Joachim Mertens

University Hospital Zürich,
Zürich, Switzerland

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Dr Coralie Sayag

Former Medical Director Solid Tumours,
Region Europe, Incyte Biosciences International Sàrl (01 May 2020 – 31 May 2022)

Perspectives on precision medicine in CCA (2021)

Listen to Professor Eric Van Cutsem and Dr Angela Lamarca provide expert perspectives on key questions in precision medicine and molecular testing in advanced CCA

Professor Eric Van Cutsem

University Hospitals Gasthuisberg Leuven and
KU Leuven, Belgium

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Company/Organisation	Relationship(s)
Personal financial interests:
Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience, Inc, Janssen, Lilly, Marketing Farmacéutico & Investigación Clínica, S.L, MDS, Medscape, Novocure, Paraxel, PPD Development, Polaris, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier, Scilink Comunicación Científica SC, Surface Oncology, Swedish Orpahn Biovitrum AB, Zymeworks	Advisory role Speaker’s fee Direct research fund
Institutional financial interests:
AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amc Medical Research, Amgen, Armo Biosciences, Aslan Pharmaceuticals, Astrazeneca, Basilea Pharmaceutica International, Bayer, Beigene, Biokeralty Research Institute, Biolinerx, Blueprint Medicines, Boston Biomedical, Bristol-Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-la Roche, Fibrogen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma, Lilly, Loxo Oncology, Medimmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks	Clinical trial support

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boston Scientific, EISAI, Ipsen, QED, Nutricia, Roche, Servier	Consulting honoraria
AAA pharmaceuticals, AstraZeneca, EISAI, Incyte, Ipsen, QED, Merck, Pfizer, Servier	Speaker honoraria
AAA pharmaceutical, Bayer, Delcath Systems, Ipsen, Mylan, Novartis, Pfizer, Sirtex Medical	Travel, education funding

Company/Organisation	Relationship(s)
Incyte	Consultant
Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier	Research grants
Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex Medical, Taiho	Advisory boards

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boston Scientific, EISAI, Ipsen, QED, Nutricia, Roche, Servier	Consulting honoraria
AAA pharmaceuticals, AstraZeneca, EISAI, Incyte, Ipsen, QED, Merck, Pfizer, Servier	Speaker honoraria
AAA pharmaceutical, Bayer, Delcath Systems, Ipsen, Mylan, Novartis, Pfizer, Sirtex Medical	Travel, education funding

Expert perspectives on cholangiocarcinoma (CCA)

CCA: under the spotlight (2021)

Perspectives on precision medicine in CCA (2021)

All videos in this category

CCA: under the spotlight (2021)

Perspectives on precision medicine in CCA (2021)

Enhance your CCA knowledge with Incyteful